Phase II Study of Surgery Combined With Recombinant Adenoviral Human p53 Gene Therapy in Treatment Advanced Non-small-cell Carcinoma
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
overall survival
determine the 3-years overall survival
3 year after the treatment
No
Qunyou Tan, M.D., Ph.D
Principal Investigator
Institute of Surgery Research, Daping Hospital, Third Military Medical University
China: Military Health Department
rAd-p53NSCLC
NCT01574729
August 2012
October 2015
Name | Location |
---|